Ionis: Positive data for ETESIAN Phase 2b study of antisense med targeting PCSK9 at ACC

 

• ETESIAN Phase 2b study of ION449 (AZD8233) met its primary and secondary endpoints; ION449 was generally well tolerated
• ION449 demonstrated potential best-in-class efficacy profile for a self-administered subcutaneous monthly dose regimen
• Study findings warrant further clinical development of ION449 for patients with hypercholesterolemia at high cardiovascular risk

https://www.biospace.com/article/releases/ionis-announces-positive-data-for-etesian-phase-2b-study-of-antisense-medicine-targeting-pcsk9-at-2022-american-college-of-cardiology-scientific-session/